PT - JOURNAL ARTICLE AU - SOICHIRO MORINAGA AU - YOSHIYASU NAKAMURA AU - YOHEI ATSUMI AU - MASAAKI MURAKAWA AU - KOICHIRO YAMAOKU AU - TORU AOYAMA AU - SATOSHI KOBAYASHI AU - MAKOTO UENO AU - MANABU MORIMOTO AU - TOMOYUKI YOKOSE AU - YOHEI MIYAGI TI - Locked Nucleic Acid <em>In Situ</em> Hybridization Analysis of MicroRNA-21 Predicts Clinical Outcome in Patients After Resection for Pancreatic Cancer Treated with Adjuvant Gemcitabine Monotherapy DP - 2016 Mar 01 TA - Anticancer Research PG - 1083--1088 VI - 36 IP - 3 4099 - http://ar.iiarjournals.org/content/36/3/1083.short 4100 - http://ar.iiarjournals.org/content/36/3/1083.full SO - Anticancer Res2016 Mar 01; 36 AB - Background: The overexpression of microRNA-21 (miR-21) in pancreatic cancer has been implicated in drug resistance to gemcitabine. Thus far, miR-21 has gained wide attention as a potential biomarker to predict the clinical response in patients with pancreatic cancer receiving gemcitabine. The aim of this study was to evaluate the predictive value of miR-21 expression, determined by locked nucleic acid in situ hybridization (LNA-ISH), in patients with pancreatic cancer who underwent adjuvant gemcitabine after curative surgery. Materials and Methods: Tumor miR-21 expression was analyzed via LNA-ISH and correlated with the clinical outcomes of the patients treated with adjuvant gemcitabine. Results: The overexpression of miR-21 in pancreatic cancer, determined by LNA-ISH, was significantly and independently associated with a shorter disease-free survival in patients who received adjuvant gemcitabine after curative resection. Conclusion: The LNA-ISH analysis of miR-21 may serve as a significant predictor for gemcitabine resistance in patients with pancreatic cancer undergoing adjuvant gemcitabine after curative resection.